New hope for painful skin ulcers: experimental drug enters human trials

NCT ID NCT07444684

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests an injection called SHR-1139 in 20 adults with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The goal is to see if the drug can completely close the ulcers and how safe it is. Researchers will also measure how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SHR-1139 injection
What this could lead to
If successful, this could point toward a new treatment option for pyoderma gangrenosum, a painful skin ulcer condition with limited therapies.
What could go wrong
This is a small early-phase trial with only 20 participants, so results may not apply to everyone. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PYODERMA GANGRENOSUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shandong First Medical University Affiliated Dermatology Hospital

    Jinan, Shandong, 250022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.